Autoimmunity and the risk of myeloproliferative neoplasms. - Test2 - elhamkhani - TriplyDB

Autoimmunity and the risk of myeloproliferative neoplasms.

Autoimmunity and the risk of myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q33952854

about

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives The Hen or the Egg: Inflammatory Aspects of Murine MPN Models The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.Risk of myeloid neoplasms after solid organ transplantation.Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms Cancer risk in immune-mediated inflammatory diseases (IMID).Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.Cellular and molecular mechanisms of autoimmune disease.Inheritance of the chronic myeloproliferative neoplasms. A systematic review.Inherited predisposition to myeloproliferative neoplasms Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.An immune dysregulation in MPN.MDS and GCA: a prognostic dilemma.Immunological Consequences of JAK Inhibition: Friend or Foe?Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Impact of inflammation on early hematopoiesis and the microenvironment.Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease.Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report.Smoking and philadelphia-negative chronic myeloproliferative neoplasms.Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.No association between myeloproliferative neoplasms and the Crohn's disease-associated STAT3 predisposition SNP rs744166.Myeloproliferative neoplasms in five multiple sclerosis patients.Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation.Association between rheumatic diseases and cancer: results from a clinical practice cohort study.Community-acquired infections and their association with myeloid malignancies.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies.Expression of CD markers in JAK2 positive myeloproliferative neoplasms: Prognostic significance

P2860

Q26775996-682276A4-5E96-4F1F-8730-335D415174A9 Q26778931-5523EAAD-5F32-4CDD-9C43-85847D9B0F85 Q26779929-4698B67B-4BF8-4B23-9BB8-1F47EB142A55 Q26779936-CAAA7D15-966A-4DC6-8D54-0D32DDE7C107 Q26779960-C2DF8273-23EF-4406-B1F6-FA42EF207754 Q27687340-E59F4EF1-D83F-4418-A771-A4E62A44B5C5 Q30592352-A8E8E0B6-CCAD-4649-84C9-3CE1642D147F Q33775211-5F51C073-338E-4B3E-83A3-5D0EC9A2F337 Q35112330-B303DF0C-4CA3-431C-A25E-2F59938738DB Q35113804-F2D52CEC-201F-4D0B-A95C-D51EDB5175BA Q35665103-4EB2BF32-AD88-40AD-9D14-42D7D322F746 Q35841839-A3FC7B3A-0B29-443B-BDD9-377851DEEFA5 Q37153407-C31C3D27-F36C-419C-81BF-8CE5D9E95AF3 Q37625875-8ED9D166-B35F-4D48-B79D-65396552A674 Q37955142-8A426F6E-7D60-4949-AE45-F9F3974EC989 Q37959331-9B54723B-D6DD-4C27-B329-0CEFF7A2C356 Q38055219-7FF5B820-5CCD-47C0-B89C-4C76BC4C5E5A Q38127417-62A2AC77-7014-4BC6-8B18-75D00672B41F Q38187674-FDD2A7A6-3EB9-4FEF-A9D7-615E79B4CF06 Q38241495-23B67E40-6796-4917-8CE5-F2B3BA38AC56 Q38529556-C9BCF2A6-FFF2-4198-9E14-7840E6211AD4 Q38570383-835688B7-EB7D-49C0-8C9F-C0D638EFC86A Q38706624-72EC9B48-E32B-400B-9223-597DA498CA72 Q39339795-4D689C2D-4028-4AB7-943D-23623D33FCB4 Q39722432-2EBD121B-885B-47B4-BC7B-5DA3E8B3F36C Q40489397-FAF5F558-7485-4659-9C93-9053611DDDFE Q41229628-1439FA29-AAA9-48D3-800D-1C9C743C7A64 Q41348010-2F94614C-7ADB-4B8D-B1BE-24C368CCC7C4 Q41576528-A263510C-0D53-478D-B4F2-C83866064273 Q42221121-828C9C3E-7266-4A43-9DEC-4C807DCCF583 Q42739949-734EBC47-AA3C-4D65-98DF-BD0E89656CE9 Q42847809-191825A4-FD7F-410B-9DF6-C68BA1D9D043 Q44358944-B69F8DF6-DEF8-4918-AB78-51FFEDC2BF6E Q46891342-67E15FE3-8C93-4E85-8FAD-4C2F866AFE5B Q49324407-91DF479C-4E41-4169-8DB6-A7EB3C768C95 Q50216701-B5ED3FF6-B6CD-46E3-B588-983C3E23CA2F Q53081575-0744B5F3-387E-4444-B813-FB5E9E737EBA Q53680800-06C9ACFE-9942-451D-86D6-A3C6759BA38D Q55024258-3EB83E78-E2C1-4CDC-BAC1-D8EAFE15A08B Q58587352-6450ECA0-2F1B-4180-AB21-C73F050967BA

P2860

Autoimmunity and the risk of myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q33952854

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Autoimmunity and the risk of myeloproliferative neoplasms.

@ast

Autoimmunity and the risk of myeloproliferative neoplasms.

@en

type

label

Autoimmunity and the risk of myeloproliferative neoplasms.

@ast

Autoimmunity and the risk of myeloproliferative neoplasms.

@en

prefLabel

Autoimmunity and the risk of myeloproliferative neoplasms.

@ast

Autoimmunity and the risk of myeloproliferative neoplasms.

@en

P1433

Q33952854-B2AC3ADC-2FD6-46CF-9437-73B5375CD764

P1476

Q33952854-34A6BE36-F017-4463-9E60-BF6F4FD9E86C

P2093

Q33952854-20046B58-ADBF-4BE9-BAEC-E25BFF36C124

Q33952854-5F102BF5-F48E-4972-86E0-D513F06D2807

Q33952854-89BEADB3-1CDC-4DDB-830E-F13C39C9375D

Q33952854-A7A62C29-8D7C-44A1-84AD-09637399BE00

P2860

Q33952854-04A67E6D-C276-4C3E-B655-F5EF5B6DA976

Q33952854-0963F2AB-359B-4229-8F58-06B058E0DA2A

Q33952854-0E7280A4-8E1F-4037-B363-E0890E77FEC8

Q33952854-11F4BC08-9DA0-40B3-B8BB-D23B23FA52E3

Q33952854-13B50D55-E89C-41FF-8D1E-150803C8921D

Q33952854-20BD7F70-5174-47A8-B9A0-BA3226CBA044

Q33952854-2A03867F-399F-47AE-9E80-6ADBC517FDA8

Q33952854-2A762539-FDF8-48B7-B452-FC22F1F27DF4

Q33952854-4C0FE694-A9D9-4346-BFBA-23439ADBFCCA

Q33952854-6D26CA8A-5B30-4A97-8C31-8DAA8CE55653

P304

Q33952854-A4951C2D-BECB-4D01-9CDE-6095717E8440

P31

Q33952854-421661B4-D4F7-49D4-8221-D67247961068

P356

Q33952854-8AC826DF-B0E8-4679-9221-F0C07539E901

P433

Q33952854-FD39A7B0-0B9B-485E-90D3-125F9004F05D

P478

Q33952854-31DEE40A-227B-4C93-8328-5A9DF3BB4183

P50

Q33952854-7136A36C-11C7-4FBC-B31F-14BAB98F88CD

P577

Q33952854-3594880E-4B51-466C-B002-BCB172E36000

P5875

Q33952854-6421F6C3-63AB-4BB7-9D1E-6CA06CEB6526

P698

Q33952854-4986FC43-D81B-4AEC-A376-3C71BA9E7156

P932

Q33952854-EDA66154-8B71-4BB2-AD38-5F079464FABD

P356

HAEMATOL.2009.020412

P1433

P1476

Autoimmunity and the risk of myeloproliferative neoplasms.

@en

P2093

Jan Samuelsson

http://www.w3.org/2001/XMLSchema#string

Lynn R Goldin

http://www.w3.org/2001/XMLSchema#string

Magnus Björkholm

http://www.w3.org/2001/XMLSchema#string

Sigurdur Y Kristinsson

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

Development of polycythemia vera and chronic lymphocytic leukemia during the course of refractory idiopathic thrombocytopenic purpura.

Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias.

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Essential thrombocythemia: a review of diagnostic and pathologic features.

The risk of cancer in patients with Crohn's disease.

Oncogenes in myeloproliferative disorders.

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

P304

1216-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2009.020412

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40869815

http://www.w3.org/2001/XMLSchema#string

P698

20053870

http://www.w3.org/2001/XMLSchema#string

P932

2895049

http://www.w3.org/2001/XMLSchema#string